Cefotetan An official website of the United States government Here's how you know Log inAccess keysNCBI HomepageMyNCBI HomepageMain ContentMain NavigationBookshelfSearch databaseBooksAll DatabasesAssemblyBiocollectionsBioProjectBioSampleBooksClinVarConserved DomainsdbGaPdbVarGeneGenomeGEO DataSetsGEO ProfilesGTRHomoloGeneIdentical Protein GroupsMedGenMeSHNLM and EffectsSummary of Use during LactationCefotetan is no longer marketed in the United States. Amoderate amount of information indicates that cefotetan produces low levels in milk that are not expected to cause adverse effects in breastfed infants. Occasionally disruption of the infant's gastrointestinal flora, resulting in diarrhea or thrush have been reported with cephalosporins, but these effects have not been
Pharmacokinetics and Tolerability of Single and Multiple Intravenous Doses of Cefotetan Disodium in Healthy Chinese Volunteers. Cefotetan is highly stable to penicillinase and cephalosporin produced by gram-negative bacteria, and it has strong antimicrobial activity against most gram-negative bacteria, some anaerobic bacteria and streptococcus. The objective of this study was to evaluate the pharmacokinetic profile and tolerability of single and multiple intravenous doses of cefotetan disodium in healthy Chinese volunteers. In this single-center, open-label, dose-escalating study, subjects were randomized to receive a single dose of cefotetan disodium 0.5, 1.0, or 2.0 g administered as a 1 h intravenous infusion. After completion of the single-dose phase, subjects continued into the multiple-dose
Immunologic Evaluation of Patients with Cefotetan-Induced Anaphylaxis Cefotetan is a commonly prescribed second-generation cephalosporin that acts against a wide range of bacteria. However, cefotetan-induced hypersensitivity has rarely been reported. We report 2 cases of cefotetan-induced anaphylaxis with immunologic evaluation. The first case was a 70-year-old asthmatic woman who had dyspnea and hypotension during administration of cefotetan, in which high serum-specific IgE to cefotetan-human serum albumin (HSA) conjugate was detected by enzyme-linked immunosorbent assay. The second case was a 63-year-old asthmatic woman who complained of chest tightness and dyspnea during cefotetan infusion, in which high serum-specific IgG1 and IgG4 with no serum specific IgE to cefotetan-HSA conjugate
of infections caused by ESBL-E? Suggested approach: Cephamycins are not suggested for the treatment of ESBL-E infections until more clinical outcomes data using cefoxitin or cefotetan are available and optimal dosing has been defined. Rationale The cephamycins are cephalosporins that are generally able to withstand hydrolysis from ESBL enzymes114,115. The cephamycins available in the United States are cefoxitin and cefotetan which are both IV agents. At least ten observational studies have compared the clinical outcomes of patients with Last updated December 31, 2023, and posted online at guidance/. Please check website for most updated version of this guidance. 22 ESBL-E infections—generally UTIs or bloodstream infections from urinary sources—treated with cephamycins versus carbapenems 116-125. Eight
for the treatment of ESBL-E infections until more clinical outcomes data using cefoxitin or cefotetan are available and optimal dosing has been defined. Rationale The cephamycins are cephalosporins generally able to withstand hydrolysis from ESBL enzymes[102, 103]. The cephamycins available in the United States are cefoxitin and cefotetan which are both IV agents. At least eight retrospective observational numbers of patients received cefoxitin or cefotetan in published studies [107, 111, 112]. The panel believes more clinical data associated with these agents for the treatment of ESBL-E infections is necessary before advocating for their use—including optimal dosing and frequency of administration—especially in light of the two observational studies suggesting poorer clinical outcomes with cephamycin use
: Cephamycins are not recommended for the treatment of ESBL-E infections until more clinical outcomes data using cefoxitin or cefotetan are available and optimal dosing has been defined.RationaleThe cephamycins are cephalosporins that are generally able to retain in vitro activity against ESBL enzymes[78, 79]. The cephamycins available in the United States are cefoxitin and cefotetan which are both in observational studies are not available in the United States. Only 31 patients received cefoxitin (and none received cefotetan) in published studies [83, 87]. The panel believes more clinical data with use of these agents for the treatment of ESBL-E infections is necessary before recommending their use—including optimal dosing and frequency of administration—especially in light of the two observational
to draw attention to the dissimilarities. The following table, showing TML drug names of easily confused medication names that may be administered by the anesthesia care team during a procedure, is taken from lists compiled by the FDA and ISMP.16,17ceFAZolin dexameTHASONE DOBUTamine HumaLOG* cefoTEtan dexmedeTOMidine DOPamine HumuLIN* cefOXitin
revealed that the most common sequence types (STs) were ST69 (12.5%), ST131 (8.2%), and ST1193 (7.8%). In our hospital, E. coli was resistant to most commonly used antibiotics, and cefoperazone/sulbactam, cefotetan, amikacin, and tigecycline were empirically selected for the treatment of bloodstream infections. The predominant ESBL genotype in our hospital was bla and the major quinolone resistance gene
the NCBI database with Abricate. Plasmid replicon types were identified using PlasmidFinder, available at the Center for Genomic Epidemiology.. Five CR-PMI strains collected in our hospital from July 2019 to September 2021 were resistant to almost all antimicrobial agents except aztreonam (ATM), amikacin (AMK) and cefotetan (CTT). All CR-PMI strains contained the carbapenem resistance gene New Delhi
), 94% (29/31) and 97% (30/31) respectively. The drug resistance rates of ampicillin, ampicillin-sulbactam and trimethoprim-sulfamethoxazole were 51% (16/31), 48% (15/31) and 48% (15/31) respectively, those of cefazolin, cefotetan, tobramycin, gentamicin and amikacinwere all 100% (31/31). There were no significant differences in the drug resistance rates of ceftazidime, ceftriaxone, aztreonam
after cesarean section? Am J Obstet Gynecol 1998;179:1261–6. Article Locations:Article Location 34. Chapman SJ, Owen J. Randomized trial of single-dose versus multiple-dose cefotetan for the postpartum treatment of intrapartum chorioamnionitis. Am J Obstet Gynecol 1997;177:831–4. Article Locations:Article Location 35. Polin RA. Management of neonates with suspected or proven early-onset
Hydrochlorothiazide 3 Amlodipine 3 Ramipril 3 Enalapril 2 Other 10 Alimentary Omeprazole 2 Other 2 1 Miscellaneous 12 Total 104 84 Table II. Distribution of cases of drug induced haemolytic anaemia in 2 major series † (Garbe 2011), * (Garratty 2010). Both presented 10-year data (2000-2009). In the series of Garratty, 36 cases (43%) were due to cefotetan, an antibiotic